Showing results (171-180 of 288) with videos related to
Sort By:
Pageof 29
British Journal of Haematology|June 19, 2021
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemiaPeter H Wiernik, Zhuoxin Sun, Larry D Cripe, et al.Lancet (London, England)|February 21, 2004
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemiaAdolfo A Ferrando, Donna S Neuberg, Richard K Dodge, et al.Nature Communications|September 14, 2021
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitorsAli Khateb, Anagha Deshpande, Yongmei Feng, et al.Journal of Crohn'S & Colitis|November 18, 2021
Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRNOhad Atia, Sasha Harel, Natan Ledderman, et al.British Journal of Haematology|April 30, 2015
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.Proceedings of the National Academy of Sciences of the United States of America|February 9, 2017
Synergistic antileukemic therapies in NOTCH1-induced T-ALLMarta Sanchez-Martin, Alberto Ambesi-Impiombato, Yue Qin, et al.Blood|March 19, 2011
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinHugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.Bone Marrow Transplantation|August 8, 2023
Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I studyJoseph P McGuirk, Leland Metheny, Luis Pineiro, et al.Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.Pageof 29